 Late last week, Atara Biotherapeutics Inc NASDAQ: ATRA announced that Bayer AG OTC: BAYRY intends to terminate the exclusive worldwide licensing agreement for Ataras mesothelin-targeted allogeneic and autologous CAR-T assets, ATA3271 and ATA2271. The. 